2-(1H-吲唑-3-基)-乙酰胺 | 103755-46-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 2-(1H-吲唑-3-基)-乙酰胺
• 英文名称: 2-(1(2)H-indazol-3-yl)-acetamide
• 英文别名: 2-(1H-indazol-3-yl)-acetamide；2-(1H-indazolyl)acetamide；indazole-3-acetamide；Indacyl-(3)-essigsaeure-amid；2-(1h-Indazol-3-yl)acetamide；2-(2H-indazol-3-yl)acetamide
• CAS: 103755-46-0
• 化学式: C₉H₉N₃O
• 分子量: 175.19
• InChiKey: HMHXWCRWPMARLE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  71.8
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(1H-吲唑-3-基)-乙酰胺 在 potassium tert-butylate 、 caesium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.67h， 生成 3-[1-(3-hydroxypropyl)-1H-indazol-3-yl]-4-[1-(2-naphthalenyl)-1H-indol-3-yl]-1H-pyrrole-2,5-dione
  参考文献：
  名称：

  Novel Indolylindazolylmaleimides as Inhibitors of Protein Kinase C-β:  Synthesis, Biological Activity, and Cardiovascular Safety

  摘要：

  Novel indolylindazolylmaleimides were synthesized and examined for kinase inhibition. We identified low-nanomolar inhibitors of PKC-beta with good to excellent selectivity vs other PKC isozymes and GSK-3 beta. In a cell-based functional assay, 8f and 8i effectively blocked IL-8 release induced by PKC-beta II (IC50 = 20-25 nM). In cardiovascular safety assessment, representative lead compounds bound to the hERG channel with high affinity, potently inhibited ion current in a patch-clamp experiment, and caused a dose-dependent increase of QT(c) in guinea pigs.

  DOI：

  10.1021/jm049478u
• 作为产物：
  描述：

  吲唑-3-乙酸 在 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 、 ammonium hydroxide 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 以67%的产率得到2-(1H-吲唑-3-基)-乙酰胺
  参考文献：
  名称：

  Novel Indolylindazolylmaleimides as Inhibitors of Protein Kinase C-β:  Synthesis, Biological Activity, and Cardiovascular Safety

  摘要：

  Novel indolylindazolylmaleimides were synthesized and examined for kinase inhibition. We identified low-nanomolar inhibitors of PKC-beta with good to excellent selectivity vs other PKC isozymes and GSK-3 beta. In a cell-based functional assay, 8f and 8i effectively blocked IL-8 release induced by PKC-beta II (IC50 = 20-25 nM). In cardiovascular safety assessment, representative lead compounds bound to the hERG channel with high affinity, potently inhibited ion current in a patch-clamp experiment, and caused a dose-dependent increase of QT(c) in guinea pigs.

  DOI：

  10.1021/jm049478u

文献信息

• Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors
  申请人：Zhang Han-Cheng

  公开号：US20050004201A1

  公开（公告）日：2005-01-06

  The present invention is directed to novel indazolyl-substituted pyrroline compounds of Formula (I): R 2 is selected from the group consisting of —C 1-8 alkyl-Z, —C 2-8 alkenyl-Z and —C 2-8 alkynyl-Z; wherein the —C 1-8 alkyl-Z, —C 2-8 alkenyl-Z and —C 2-8 alkynyl-Z and Z is a 5 to 6 member aromatic monocyclic heteroaryl ring having from 2 to 4 heteroatoms. These compounds are useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.

  本发明涉及一种新型的Formula (I)的吲唑基取代的吡咯烯化合物：R2选自由—C1-8烷基-Z，—C2-8烯基-Z和—C2-8炔基-Z组成的群；其中—C1-8烷基-Z，—C2-8烯基-Z和—C2-8炔基-Z以及Z是一个含有2到4个杂原子的5到6成员芳香单环杂环烷基环。这些化合物可用作激酶或双激酶抑制剂，用于生产这种化合物的方法以及治疗或改善激酶或双激酶介导的疾病的方法。
• Indazolyl-substituted pyrroline compounds as kinase inhibitors
  申请人：Zhang Han-Cheng

  公开号：US20080096949A1

  公开（公告）日：2008-04-24

  The present invention is directed to novel indazolyl-substituted pyrroline compounds of Formula (I): useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.

  本发明涉及新型的取代吲唑基吡咯烷化合物，化学式为(I)：用作激酶或双重激酶抑制剂，制备这种化合物的方法以及用于治疗或改善激酶或双重激酶介导的疾病的方法。
• THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY
  申请人：Kubo Kazuo

  公开号：US20090270391A1

  公开（公告）日：2009-10-29

  An objective of the present invention is to provide compounds having antitumor activity. According to the present invention, there is provided compounds represented by formula (I) and pharmaceutically acceptable salts thereof, and solvates thereof: wherein R 1 represents H or a substitutable unsaturated five- or six-membered heterocyclic ring; R 2 represents H; X represents CH or N; Z represents O or S; E is absent or represents halogen, alkyl, or alkoxy; J represents S or O; and T represents phenyl, an unsaturated five- or six-membered heterocyclic ring, an unsaturated nine- or ten-membered bicyclic carbocyclic ring or heterocyclic ring.

  本发明的目标是提供具有抗肿瘤活性的化合物。根据本发明，提供了由公式（I）表示的化合物及其药学上可接受的盐和溶剂化物：其中，R1代表H或可取代的不饱和五元或六元杂环环；R2代表H；X代表CH或N；Z代表O或S；E不存在或代表卤素，烷基或烷氧基；J代表S或O；T代表苯基，不饱和五元或六元杂环环，不饱和九元或十元双环碳环或杂环环。
• SUBSTITUTED PYRROLINE KINASE INHIBITORS
  申请人：Zhang Han-Cheng

  公开号：US20090181982A1

  公开（公告）日：2009-07-16

  The present invention is directed to novel substituted pyrroline compounds useful as kinase inhibitors and methods for treating or ameliorating a kinase mediated disorder.

  本发明涉及一种新的取代吡咯烷化合物，可用作激酶抑制剂，并用于治疗或改善激酶介导的疾病的方法。
• THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING C-MET AUTOPHOSPHORYLATION INHIBITING POTENCY
  申请人：Kirin Pharma Kabushiki Kaisha

  公开号：EP1870414A1

  公开（公告）日：2007-12-26

  An objective of the present invention is to provide compounds having antitumor activity. According to the present invention, there is provided compounds represented by formula (I) and pharmaceutically acceptable salts thereof, and solvates thereof: wherein R1 represents H or a substitutable unsaturated five- or six-membered heterocyclic ring; R2 represents H; X represents CH or N; Z represents O or S; E is absent or represents halogen, alkyl, or alkoxy; J represents S or O; and T represents phenyl, an unsaturated five- or six-membered heterocyclic ring, an unsaturated nine- or ten-membered bicyclic carbocyclic ring or heterocyclic ring.

  本发明的目的是提供具有抗肿瘤活性的化合物。根据本发明，提供了式 (I) 所代表的化合物及其药学上可接受的盐类，以及其溶液： 其中 R1 代表 H 或可取代的不饱和五元或六元杂环；R2 代表 H；X 代表 CH 或 N；Z 代表 O 或 S；E 不存在或代表卤素、烷基或烷氧基；J 代表 S 或 O；T 代表苯基、不饱和五元或六元杂环、不饱和九元或十元双环碳环或杂环。